Sarepta Therapeutics FDA Panel Live Blog
By Adam Feuerstein
04/25/16
http://www.thestreet.com/story/13541457/1/sarepta-therapeutics-fda-panel-live-blog.html
Monday is a crucial day for Sarepta Therapeutics (SRPT - Get Report) .
The live blog above is tracking all the action at a U.S. Food and Drug Administration advisory committee meeting, convened to review eteplirsen, Sarepta's experimental drug for the treatment of Duchenne muscular dystrophy.
TheStreet Senior Columnist Adam Feuerstein is providing live coverage and analysis of the Sarepta FDA advisory panel as it happens near Washington, D.C.
At the end of Monday's meeting, a panel of 13 independent experts will vote on a series of questions which will provide recommendation to the FDA on whether or not eteplirsen should be approved, or not.
Sarepta shares are halted for trading while the advisory panel is in session. The stock last traded Friday at $14.95.

Gold is $1,581/oz today. When it hits $2,000, it will be up 26.5%. Let's see how long that takes. - De 3/11/2013 - ANSWER: 7 Years, 5 Months